New study involving the use of selinexor to overcome ibrutinib resistance is seen as a “breakthrough” by some people who are undoubtedly smarter than me. Interesting stuff, the plain English explanation is contained at “Breakthrough Increases Efficacy of B-Cell Lymphoid Malignancy Treatment”.
ajmc.com/newsroom/breakthro...
The far more complicated study itself is at “Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies”.
researchgate.net/publicatio...
I would like to think of this as a Christmas present for those of us who have encountered Ibrutinib resistance.
Merry Christmas,
Owen